Expert Opinion on Emerging Drugs · 2020 · 48 citations · 27 references
Life SciencesNeurologyPharmacotherapyInflammationNeurodegenerationNeuroimmunologyDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisNeurodegenerative DiseasesNeuroinflammationTyrosine Kinase InhibitorsBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsChronic Inflammatory InjuryMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis PathologyMultiple Sclerosis TherapyNeuroinflammation In Multiple SclerosisTherapeutic Tyrosine Kinase Inhibitors
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) leading to demyelination and neurodegeneration. Although its etiology is not fully understood yet, gene...
27
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis, Jeremy P. Hunt, Sanna Herrgård et al. · Nature Biotechnology · 2011 · 2.4K citations · Full text
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis
Hans Neubauer, Ana Cumano, Mathias Müller et al. · Cell · 1998 · 915 citations · Full text
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi, Michael I. Jesson, Li Xiong et al. · The Journal of Immunology · 2011 · 644 citations · Full text